|
1.
|
Lawrence TS, Tepper JE and Blackstock AW:
Fluoropyrimidine-radiation interactions in cells and tumors. Semin
Radiat Oncol. 7:260–266. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Pignon JP, Bourhis J, Domenge C and
Designe L: Chemotherapy added to locoregional treatment for head
and neck squamous-cell carcinoma: three meta-analyses of updated
individual data. MACH-NC Collaborative Group. Meta-analysis of
chemo-therapy on head and neck cancer. Lancet. 355:949–955. 2000.
View Article : Google Scholar
|
|
3.
|
Adelstein DJ, Saxton JP, Rybicki LA, et
al: Multiagent concurrent chemoradiotherapy for locoregionally
advanced squamous cell head and neck cancer: mature results from a
single institution. J Clin Oncol. 24:1064–1071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Tsukuda M, Ishitoya J, Matsuda H, et al:
Randomized controlled phase II comparison study of concurrent
chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil
versus CCRT with cisplatin, 5-fluorouracil, methotrexate and
leucovorin in patients with locally advanced squamous cell
carcinoma of the head and neck. Cancer Chemother Pharmacol.
66:729–736. 2010.
|
|
5.
|
Shingaki S, Takada M, Sasai K, et al:
Impact of lymph node metastasis on the pattern of failure and
survival in oral carcinomas. Am J Surg. 185:278–284. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Bell RB, Kademani D, Homer L, Dierks EJ
and Potter BE: Tongue cancer: Is there a difference in survival
compared with other subsites in the oral cavity? J Oral Maxillofac
Surg. 65:229–236. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Colevas AD: Chemotherapy options for
patients with metastatic or recurrent squamous cell carcinoma of
the head and neck. J Clin Oncol. 24:2644–2652. 2006. View Article : Google Scholar
|
|
8.
|
Gibson MK, Li Y, Murphy B, et al:
Randomized phase III evaluation of cisplatin plus fluorouracil
versus cisplatin plus paclitaxel in advanced head and neck cancer
(E1395): an intergroup trial of the Eastern Cooperative Oncology
Group. J Clin Oncol. 23:3562–3567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kang HC, Kim IJ, Park JH, et al:
Identification of genes with differential expression in acquired
drug-resistant gastric cancer cells using high-density
oligonucleotide microarrays. Clin Cancer Res. 10:272–284. 2004.
View Article : Google Scholar
|
|
10.
|
Herrmann R: 5-Fluorouracil in colorectal
cancer, a never ending story. Ann Oncol. 7:551–552. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ
and Park JG: Metabotropic glutamate receptor 4-mediated
5-fluorouracil resistance in a human colon cancer cell line. Clin
Cancer Res. 10:4176–4184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Wang W, Cassidy J, O’Brien V, Ryan KM and
Collie-Duguid E: Mechanistic and predictive profiling of
5-fluorouracil resistance in human cancer cells. Cancer Res.
64:8167–8176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Petersen SL, Peyton M, Minna JD and Wang
X: Overcoming cancer cell resistance to Smac mimetic induced
apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA.
107:11936–11941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Meads MB, Gatenby RA and Dalton WS:
Environment-mediated drug resistance: a major contributor to
minimal residual disease. Nat Rev Cancer. 9:665–674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Denys H, Braems G, Lambein K, et al: The
extracellular matrix regulates cancer progression and therapy
response: implications for prognosis and treatment. Curr Pharm Des.
15:1373–1384. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cukierman E and Bassi DE: The mesenchymal
tumor microenvironment: a drug-resistant niche. Cell Adh Migr.
6:285–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Hynes RO: Integrins: bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Aoudjit F and Vuori K: Integrin signaling
inhibits paclitaxel-induced apoptosis in breast cancer cells.
Oncogene. 20:4995–5004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Damiano JS: Integrins as novel drug
targets for overcoming innate drug resistance. Curr Cancer Drug
Targets. 2:37–43. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lewis JM, Truong TN and Schwartz MA:
Integrins regulate the apoptotic response to DNA damage through
modulation of p53. Proc Natl Acad Sci USA. 99:3627–3632. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Sethi T, Rintoul RC, Moore SM, et al:
Extracellular matrix proteins protect small cell lung cancer cells
against apoptosis: a mechanism for small cell lung cancer growth
and drug resistance in vivo. Nat Med. 5:662–668. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hannigan G, Troussard AA and Dedhar S:
Integrin-linked kinase: a cancer therapeutic target unique among
its ILK. Nat Rev Cancer. 5:51–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shain KH and Dalton WS: Cell adhesion is a
key determinant in de novo multidrug resistance (MDR): new targets
for the prevention of acquired MDR. Mol Cancer Ther. 1:69–78.
2001.PubMed/NCBI
|
|
24.
|
Kato R, Ishikawa T, Kamiya S, et al: A new
type of anti-metastatic peptide derived from fibronectin. Clin
Cancer Res. 8:2455–2462. 2002.PubMed/NCBI
|
|
25.
|
Matsunaga T, Fukai F, Miura S, et al:
Combination therapy of an anticancer drug with the FNIII14 peptide
of fibronectin effectively overcomes cell adhesion-mediated drug
resistance of acute myelogenous leukemia. Leukemia. 22:353–360.
2008. View Article : Google Scholar
|
|
26.
|
Fukai F, Kamiya S, Ohwaki T, et al: The
fibronectin-derived anti-adhesive peptide III14-2 suppresses
adhesion and apoptosis of leukemic cell lines through
down-regulation of protein-tyrosine phosphorylation. Cell Mol Biol
(Noisy-le-grand). 46:145–152. 2000.PubMed/NCBI
|
|
27.
|
Nagata M, Nakayama H, Tanaka T, et al:
Overexpression of cIAP2 contributes to 5-FU resistance and a poor
prognosis in oral squamous cell carcinoma. Br J Cancer.
105:1322–1330. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Gentleman RC, Carey VJ, Bates DM, et al:
Bioconductor: open software development for computational biology
and bioinformatics. Genome Biol. 5:R802004. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Quackenbush J: Microarray data
normalization and transformation. Nat Genet. 32(Suppl): 496–501.
2002. View
Article : Google Scholar
|
|
31.
|
Fukai F, Hasebe S, Ueki M, et al:
Identification of the anti-adhesive site buried within the
heparin-binding domain of fibronectin. J Biochem. 121:189–192.
1997.PubMed/NCBI
|
|
32.
|
Hazlehurst LA, Damiano JS, Buyuksal I,
Pledger WJ and Dalton WS: Adhesion to fibronectin via beta1
integrins regulates p27kip1 levels and contributes to cell adhesion
mediated drug resistance (CAM-DR). Oncogene. 19:4319–4327. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Kouniavsky G, Khaikin M, Zvibel I, et al:
Stromal extracellular matrix reduces chemotherapy-induced apoptosis
in colon cancer cell lines. Clin Exp Metastasis. 19:55–60. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Uhm JH, Dooley NP, Kyritsis AP, Rao JS and
Gladson CL: Vitronectin, a glioma-derived extracellular matrix
protein, protects tumor cells from apoptotic death. Clin Cancer
Res. 5:1587–1594. 1999.
|
|
35.
|
Matsunaga T, Takemoto N, Sato T, et al:
Interaction between leukemic-cell VLA-4 and stromal fibronectin is
a decisive factor for minimal residual disease of acute myelogenous
leukemia. Nat Med. 9:1158–1165. 2003. View
Article : Google Scholar
|
|
36.
|
Helleman J, Jansen MP, Ruigrok-Ritstier K,
et al: Association of an extracellular matrix gene cluster with
breast cancer prognosis and endocrine therapy response. Clin Cancer
Res. 14:5555–5564. 2008. View Article : Google Scholar
|
|
37.
|
Jansen MP, Foekens JA, van Staveren IL, et
al: Molecular classification of tamoxifen-resistant breast
carcinomas by gene expression profiling. J Clin Oncol. 23:732–740.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Morin PJ: Drug resistance and the
microenvironment: nature and nurture. Drug Resist Updat. 6:169–172.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Miyamoto H, Murakami T, Tsuchida K, Sugino
H, Miyake H and Tashiro S: Tumor-stroma interaction of human
pancreatic cancer: acquired resistance to anticancer drugs and
proliferation regulation is dependent on extracellular matrix
proteins. Pancreas. 28:38–44. 2004. View Article : Google Scholar
|
|
40.
|
Shain KH, Landowski TH and Dalton WS: The
tumor micro-environment as a determinant of cancer cell survival: a
possible mechanism for de novo drug resistance. Curr Opin Oncol.
12:557–563. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Persad S, Attwell S, Gray V, et al:
Regulation of protein kinase B/Akt-serine 473 phosphorylation by
integrin-linked kinase: critical roles for kinase activity and
amino acids arginine 211 and serine 343. J Biol Chem.
276:27462–27469. 2001. View Article : Google Scholar
|
|
42.
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Tan C, Mui A and Dedhar S: Integrin-linked
kinase regulates inducible nitric oxide synthase and
cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J
Biol Chem. 277:3109–3116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Younes MN, Yigitbasi OG, Yazici YD, et al:
Effects of the integrin-linked kinase inhibitor QLT0267 on squamous
cell carcinoma of the head and neck. Arch Otolaryngol Head Neck
Surg. 133:15–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
